Feasibility of Using Adoptive Cell Immunotherapy to Target Differentiation of CD4+T Cells and Co-culture of DC-CIK to Kill Tumor in Vitro

Abstract

Tumor immunotherapy is a hot topic in the field of tumor therapy today. The use of CD4+T cells to enhance the killing effect of CD8+T cells and the use of DC cells for local immunotherapy are excellent methods of tumor immunotherapy, but no matter which method still have its own defects, CD4+T cells have a dual effect on CD8+T cells, and will differentiate into both tumor promoting and tumor-inhibiting phenotypes in the human body. Due to the scarce number of DC cells, it is difficult to achieve effective inhibition effect. This article mainly discusses the feasibility of in vitro culturing through adoptive cellular immunotherapy (ACI) to extract CD4 + T cells, DC and CIK cells that are inside body to solve the above problem. At the same time, the differentiation of CD4+T cells can be stronger because in vitro culture can carry out directional catalysis on single cells and avoid the influence on non-target cytokines. DC and CIK cells can play the role of local tumor inhibition and tumor killing respectively, and the combined culture can enhance their anti-tumor effect, but the number in vivo is very small, resulting in no obvious effect, the two in vitro multiplication and parallel culture can produce a stronger anti-tumor effect. Therefore, the safety and efficacy of this method in clinical application as well as the prognosis of patients still need to be further observed, and further studies can be conducted in the aspects of postoperative adaptation of ACI clinical patients.